ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Multi-omics and bulk sequencing analyses reveal the roles of prognosis and immune aspects of super-enhancer-induced ZBED2 in pan-cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundZBED2 is a member of the C2H2-zinc-finger BED-type zinc-finger protein family. However, the clinical significance and potential functions of ZBED2 in various cancers have not been systematically explored.
methodsIn this article, we comprehensively analyzed multi-omics and bulk sequencing data to explore the characteristics of ZBED2 in pan-cancer and its potential utility in cancer treatment. We investigated the expression pattern, association with prognosis, possible functions, correlation with tumor immunity, tumor-associated mutations, and drug sensitivity of ZBED2.
resultsZBED2 was significantly differentially expressed in more than 60% of the cancer types (p < 0.05). High expression of ZBED2 was an independent risk factor for a poor prognosis in many cancer patients (p < 0.05 and Hazard Ratio > 1). ZBED2 functional enrichment analysis revealed that ZBED2 expression was associated with pathways, such as immune and lipid metabolism pathways. ZBED2 expression was positively correlated with a hot immune microenvironment and was significantly correlated with immunotherapy response (p < 0.05). In addition, the overexpression of ZBED2 was negatively correlated with DNA methylation. More importantly, P300-mediated super-enhancer activity drove ZBED2 expression. Finally, we used R software to screen out 16 drugs likely to bind to ZBED2 (correlation coefficients < -0.2 and p < 0.0001) and performed molecular docking, and molecular dynamics simulation for the top six drugs.
conclusionsCollectively, by bioinformatics analysis, this study regards ZBED2 as a potential diagnostic, prognostic biomarker for many cancers and a predictive biomarker for immunotherapy, providing new insights for the application of ZBED2 in tumor targeted therapy.
Indexed as
Identifiers
41288889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.